List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

A veterinary professional or pet owner suggests including Gabapentin/Trazodone as a compounded medication for pre-operative anxiety in pets. They argue that a combined product would improve compliance and reduce stress in clinic settings.

A veterinarian with 45 years of experience is requesting the inclusion of Ponazuril on the list of bulk drug substances for compounding. They argue that the medication is necessary for the rapid treatment of life-threatening coccidia in young animals and that there is no faster alternative.

The commenter, likely a veterinarian or animal health professional, argues that GS-441524 should be added to the list of bulk drug substances for compounding. They state that because the drug is life-saving for treating feline infectious peritonitis and currently requires time-consuming external sourcing, its inclusion would prevent fatal delays in treatment for nonfood-producing animals.

A medical director at a large hospital argues that Ponazuril should be included on the list of bulk drug substances for compounding. They state that the current restrictions cause dangerous delays in treatment for small animals, and they advocate for its inclusion to ensure timely access to effective medication.

Duane Blanton, DVM, representing Wallace Animal Hospital, opposes the FDA's decision to add ponazuril to the list of drugs that cannot be sold for bulk "in clinic" use. He argues that the restriction is harmful because it delays life-saving treatment for weak small animals and that the drug is currently unavailable in a safe form for small animal use.

A feline-only veterinary hospital is opposing the removal of Ponazuril from the office stock list. They argue that the current commercial alternative is unsuitable for cats and that its removal hinders timely, cost-effective treatment for their patients.

A veterinary professional (implied by the context of "veterinary hospitals" and "available to us") is requesting that the FDA allow maropitant suspension to be included in the list of bulk drug substances for compounding. They argue that the current lack of a commercial liquid form causes unnecessary suffering for pets that cannot take pills, as waiting for compounded medication takes too long.

The American Association of Feline Practitioners (AAFP) and the American Veterinary Medical Association (AVMA) are submitting nominations to add GC 376 and GS-441524 to the list of bulk drug substances for compounding office stock drugs. They argue that these substances are necessary for the urgent treatment of Feline Infectious Peritonitis (FIP) due to limited access to approved alternatives and the need for immediate treatment to prevent animal suffering.

The commenter expresses outrage over the current state of the U.S. food system and the prevalence of chemical additives in the food supply. They advocate for closing the GRAS loophole to protect public health but do not specifically address the proposed action regarding bulk drug substances for compounding.

The commenter expresses outrage over the safety of the American food supply and the prevalence of chemical additives, citing personal health issues and national health statistics. They are calling for the closure of the "GRAS loophole" and do not address the specific action of nominating bulk drug substances for compounding.